Financial Statements — GENI
Balance Sheet
(in millions USD)| Metric | Q2
2023 |
|---|
| Cash & Equivalents | 89.81 |
| Accounts Receivable | 61.84 |
| Inventory | 0.43 |
| Total Current Assets | 222.23 |
| Property, Plant & Equipment | 11.76 |
| Goodwill | 324.55 |
| Intangible Assets | 144.91 |
| Total Non-current Assets* | 546.57 |
| Total Assets | 768.80 |
| Accounts Payable | 23.60 |
| Total Current Liabilities | 148.80 |
| Long-term Debt | 7.43 |
| Total Non-current Liabilities* | 18.74 |
| Total Liabilities | 167.54 |
| Retained Earnings | (974.42) |
| Total Stockholder Equity | 601.26 |
* Derived from reported values
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2
2023 |
|---|
| Total Revenue | 86.85 |
| Cost of Revenue | 62.17 |
| Gross Profit | 24.67 |
| Research & Development | 5.81 |
| Selling, General & Admin | 19.62 |
| Total Operating Expenses | 32.52 |
| Operating Income | (7.84) |
| Pretax Income | (6.90) |
| Tax Provision | 3.95 |
| Net Income | (10.30) |
| Basic EPS | (0.05) |
| Diluted EPS | (0.05) |
Cash Flow Statement
(in millions USD)| Metric | Q2
2023 |
|---|
| Operating Cash Flow | (22.71) |
| Capital Expenditures | 1.00 |
| Free Cash Flow* | (23.71) |
| Investing Cash Flow | (20.89) |
| Financing Cash Flow | (0.58) |
* Derived from reported values
